Polmacoxib

Polmacoxib

Polmacoxib

COX-2 selective NSAID medication

Polmacoxib (trade name Acelex) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis. It was developed as CG100649 and approved for use in South Korea in February 2015.[1] It inhibits the enzymes carbonic anhydrase and COX-2. A study in healthy volunteers showed drug effects on urinary prostaglandin metabolites for both polmacoxib and celecoxib that suggest a similar cardiovascular risk profile.[2] Further work by this group developed dose-exposure relationships of polmacoxib to guide clinical development strategies.[3]

Quick Facts Clinical data, Trade names ...

References

  1. [1]
    "CrystalGenomics Receives MFDS Approval for Acelex (Polmacoxib)" (Press release). PR Newswire.
  2. [2]
    Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA (June 2012). "Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649". Clinical Pharmacology and Therapeutics. 91 (6): 986–93. doi:10.1038/clpt.2012.3. PMC 3740579. PMID 22278334.
  3. [3]
    Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C (October 2013). "GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies". Clinical Pharmacology in Drug Development. 2 (4): 379–86. doi:10.1002/cpdd.47. PMID 27121942. S2CID 35992507.
Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Polmacoxib, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.